Intensive Tobacco Treatment for Smoking Cessation in Cancer Patients

Overseen By Kayla Fay

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Dartmouth-Hitchcock Medical Center

Disqualifiers: Unable to consent, prisoners

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

100 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this study is to assess the cessation success rates of an intensive tobacco treatment program in a patients undergoing cancer treatment at 30 days, 3 months and 6 months.

Research Team

Joseph D Phillips, MD

Principal Investigator

Dartmouth-Hitchcock Medical Center

Eligibility Criteria

This trial is for adults aged 18 or older who are actively smoking at the time of their initial cancer consultation, which means they've smoked within the last two weeks. It's not open to those unable to consent or prisoners.

Inclusion Criteria

You have been smoking within the past two weeks before your consultation for cancer.

I am 18 years old or older.

Exclusion Criteria

Prisoners

I am unable to give consent for medical procedures.

Treatment Details

Interventions

• Intensive Tobacco Treatment

Trial Overview The CORE study is testing how well an intensive tobacco treatment program helps cancer patients quit smoking. Success rates will be checked after 30 days, and then again at 3 and 6 months into the treatment.

Participant Groups

Group I: Intensive Tobacco Treatment Experimental Treatment 1 Intervention

Patients who consent to study participation will meet with a tobacco treatment specialist in-person initially, then biweekly via telephone or telehealth or face-to-face (or more frequently as needed). They will receive tobacco treatment counseling and support from certified tobacco treatment specialist, which may include pharmacotherapy as indicated. At enrollment, participants will undergo carbon monoxide testing using a carbon monoxide monitor. At baseline, participants will complete the Fagerström Test for Nicotine Dependence, and the Cancer Patient Tobacco Use Questionnaire (C-TUQ). These tobacco related survey measures will be completed at 3 additional time points: 30 days, 3 months and 6 months.

Group II: Usual Tobacco Treatment Active Control 1 Intervention

All individuals who are identified as tobacco users are offered tobacco treatment which includes proactive, as needed, contacts via in person, telehealth or telephone visits. for tobacco treatment, pharmacotherapy as indicated, and Quitline and SmokefreeTXT referrals

Who Is Running the Clinical Trial?

Dartmouth-Hitchcock Medical Center

Lead Sponsor

Trials

548

Recruited

2,545,000+